Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2309-2319

  Koudelka, Štěpán ^a   Turánek Knötigová, Pavlína ^a   Mašek, Josef ^a   Korvasová, Zina ^a   Škrabalová, Michaela ^a   Plocková, Jana ^a   Bartheldyová, Eliška ^a   Turánek, Jaroslav ^a  

^a VETERINARY RESEARCH INSTITUTE   (Czech Republic)

Author keywords

B16F10; Extrusion; Hollow fibre implants; Liposomes; Lyophilisation; Melanoma; Nanotechnology; Paclitaxel; Particle size; Stability

Indexed keywords

1 OLEOYL 2 HYDROXY SN GLYCERO 3 PHOSPHATIDYLCHOLINE; 1 PALMITOYL 2 OLEOYL SN GLYCERO PHOSPHATIDYLGLYCEROL; 1 STEAROYL 2 OLEOYL SN GLYCERO 3 PHOSPHATIDYLCHOLINE; ALPHA TOCOPHEROL; CRYOPROTECTIVE AGENT; LACTOSE; LIPOSOME; MANNITOL; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; SUCROSE; SUGAR; TREHALOSE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; CYTOTOXICITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG STABILITY; FEMALE; FREEZE DRYING; HUMAN; HUMAN CELL; IMPLANT; IN VIVO STUDY; MELANOMA; MOUSE; NANOENCAPSULATION; NONHUMAN; SINGLE DRUG DOSE; TUMOR MODEL;

EID: 77951271063     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21992     Document Type: Article

References (49)

1. Wani MC, Taylor HL, Wall ME, Coggon P, Mcphail AT. 1971. Plant antitumor agents 6. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus Brevifolia. J Am Chem Soc 93:2325-2327.
2. Schiff PB, Horwitz SB. 1980. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci 77:1561-1565.
3. Rowinsky EK, Donehower RC. 1995. Drug therapy - Paclitaxel (Taxol). N Engl J Med 332:1004-1014.
4. Lee SC, Kim C, Kwon IC, Chung H, Jeong SY. 2003. Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(epsilon-caprolactone) copolymer as a carrier for paclitaxel. J Control Release 89:437-446. (Pubitemid 36555903)
5. Feng X, Yuan YJ, Wu JC. 2002. Synthesis and evaluation of water-soluble paclitaxel prodrugs. Bioorg Med Chem Lett 12:3301-3303. (Pubitemid 35248235)
6. Liu CH, Strobl JS, Bane S, Schilling JK, McCracken M, Chatterjee SK, Rahim-Bata R, Kingston DGI. 2004. Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer. J Nat Prod 67:152-159. (Pubitemid 38282901)
7. Dosio F, Arpicco S, Brusa P, Stella B, Cattel L. 2001. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: Preparation, characterization and pharmacokinetics. J Control Release 76:107-117. (Pubitemid 32786889)
8. Lundberg BB, Risovic V, Ramaswamy M, Wasan KM. 2003. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release 86:93-100. (Pubitemid 35461976)
9. Ruan G, Feng SS. 2003. Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLAPEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials 24:5037-5044. (Pubitemid 37242983)
10. Sharma US, Balasubramanian SV, Straubinger RM. 1995. Pharmaceutical and physical-properties of paclitaxel (taxol) complexes with cyclodextrins. J Pharm Sci 84:1223-1230.
11. Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Rake J, Shaw JM, Pugh S, Polin L, Jones J, Corbett T, Cooper E, Liversidge GG. 1996. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 13:272-278. (Pubitemid 26074194)
12. Hennenfent KL, Govindan R. 2006. Novel formulations of taxanes: A review. Old wine in a new bottle? Ann Oncol 17: 735-749.
13. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. 2005. Liposomal encapsulated anticancer drugs. Anticancer drugs 16:691-707.
14. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. 2005. The liposomal formulation of doxorubicin. Methods Enzymol 391:17-97.
15. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ. 1997. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 71:103-107. (Pubitemid 27158416)
16. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I. 2005. Development and characterization of a novel Cremophor (R) EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59:177-187. (Pubitemid 39573451)
17. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L. 2000. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release 63:19-30. (Pubitemid 30046939)
18. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. 2007. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int J Pharm 338:317-326. (Pubitemid 47027038)
19. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD. 2007. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169-177. (Pubitemid 47061489)
20. Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, Shim CK, Kim DD. 2007. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res 24:2402-2411. (Pubitemid 350060715)
21. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P. 2003. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 120:476-482.
22. Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, Berghaus A, Dellian M. 2008. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 122:452-460. (Pubitemid 350234735)
23. Zhang JQ, Zhang ZR, Yang H, Tan QY, Qin SR, Qiu XL. 2005. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo studies. Pharm Res 22:573-583. (Pubitemid 40603255)
24. Needham D, Sarpal RS. 1998. Binding of paclitaxel to lipid interfaces: Correlations with interface compliance. J Liposome Res 8:147-163. (Pubitemid 28268259)
25. Turánek J, Kasna A, Zaluska D, Neca J. 2003. Preparation of sterile liposomes by proliposome-liposome method. Methods Enzymol 367:111-125. (Pubitemid 37337832)
26. Turánek J. 1994. Fast-protein liquid-chromatography system as a tool for liposome preparation by the extrusion procedure. Anal Biochem 218:352-357. (Pubitemid 24141636)
27. Song D, Hsu LF, Au JLS. 1996. Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci 85:29-31. (Pubitemid 26029067)
28. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63. (Pubitemid 14203433)
29. Bank U, Reinhold D, Ansorge S. 1991. Measurement of cellular activity by means of the MTT-test. Allerg Immunol 37:119-123.
30. Turánek J, Kasna A, Zaluska D, Neca J, Kvardova V, Knotigova P, Horvath V, Sindlerova L, Kozubik A, Sova P, Kroutil A, Zak FE, Mistr A. 2004. New platinum (IV) complex with adamantylamine ligand as a promising anti-cancer drug: Comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum (IV) complexes. Anticancer drugs 15:537-543. (Pubitemid 38736953)
31. Berlin BS. 1962. Test for biologic safety of Arlacel A. Ann Allergy 20:472-479.
32. Hall LM, Krauthauser CM, Wexler RS, Hollingshead MG, Slee AM, Kerr JS. 2000. The hollow fiber assay: Continued characterization with novel approaches. Anticancer Res 20:903-911.
33. Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA. 2004. The hollow fibre model in cancer drug screening: The NCI experience. Eur J Cancer 40:821-826. (Pubitemid 38519760)
34. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR. 1995. In-vivo cultivation of tumor-cells in hollow fibers. Life Sci 57:131-141.
35. Parhar RS, Lala PK. 1987. Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin-2. J Exp Med 165:14-28.
36. Wu J, Liu Q, Lee RJ. 2006. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 316:148-153. (Pubitemid 43786219)
37. Yang T, Cui FD, Choi MK, Lin HX, Chung SJ, Shim CK, Kim DD. 2007. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Del 14:301-308. (Pubitemid 47027038)
38. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. 2003. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 91:417-429. (Pubitemid 36980659)
39. Sharma A, Mayhew E, Straubinger RM. 1993. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor-model. Cancer Res 53:5877-5881. (Pubitemid 24006153)
40. Libondi T, Menzione M, Auricchio G. 1985. In vitro effect of α-tocopherol on lysophosphatidylcholine-induced lens damage. Exp Eye Res 40:661-666.
41. Atkinson J, Epand RF, Epand RM. 2008. Tocopherols and tocotrienols in membranes: A critical review. Free Radical Bio Med 44:739-764.
42. Kadota T, Chikazawa H, Kondoh H, Ishikawa K, Kawano S, Kuroyanagi K, Hattori N, Sakakura K, Koizumi S, Hiraiwa E, Kohmura H, Takahashi N. 1994. Toxicity studies of paclitaxel (I). Single dose intravenous toxicity in rats. J Toxicol Sci 19:1-9. (Pubitemid 24297193)
43. Murohara T, Ikeda H, Katoh A, Takajo Y, Otsuka Y, Haramaki N, Imaizumi T. 2002. Vitamin E inhibits lysophosphatidylcholine-induced endothelial dysfunction and platelet activation. Antioxid Redox Sign 4:791-798. (Pubitemid 35246942)
44. Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A. 1998. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 12:1035-1040. (Pubitemid 28186763)
45. Scialli AR, Waterhouse TB, Desesso JM, Rahman A, Goeringer GC. 1997. Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat. Teratology 56:305-310. (Pubitemid 28035176)
46. Turánek J, Wang XF, Knotigova P, Koudelka S, Dong LF, Vrublova E, Mahdavian E, Prochazka L, Sangsura S, Vacek A, Salvatore BA, Neuzil J. 2009. Liposomal formulation of α-tocopheryl maleamide: In vitro and in vivo toxicological profile and anti ancer effect against spontaneous breast carcinomas in mice. Toxicol Appl Pharmacol 237:249-257.
47. Loch-Neckel G, Nemen D, Puhl AC, Fernandes D, Stimarniglio MA, Silva MA, Hangai M, Silva MCS, Lemos-Senna E. 2007. Stealth and non-stealth nanocapsules containing camptothecin: In vitro and in vivo activity on B16F10 melanoma. J Pharm Pharmacol 59:1359-1364.
48. Lavi G, Voronov E, Dinarello CA, Apte RN, Cohen S. 2007. Sustained delivery of IL-1Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release 123:123-130.
49. Yoshiura K, Nishishita T, Nakaoka T, Yamashita N, Yamashita N. 2009. Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line. J Exp Clin Canc Res 28:13.